185 related articles for article (PubMed ID: 15057663)
1. Edotecarin.
Denny WA
IDrugs; 2004 Feb; 7(2):173-7. PubMed ID: 15057663
[TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors.
Yamada Y; Tamura T; Yamamoto N; Shimoyama T; Ueda Y; Murakami H; Kusaba H; Kamiya Y; Saka H; Tanigawara Y; McGovren JP; Natsumeda Y
Cancer Chemother Pharmacol; 2006 Aug; 58(2):173-82. PubMed ID: 16308697
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
Hurwitz HI; Cohen RB; McGovren JP; Hirawat S; Petros WP; Natsumeda Y; Yoshinari T
Cancer Chemother Pharmacol; 2007 Jan; 59(1):139-47. PubMed ID: 16819636
[TBL] [Abstract][Full Text] [Related]
4. CEP-1347 (Cephalon).
Mucke HA
IDrugs; 2003 Apr; 6(4):377-83. PubMed ID: 12789610
[No Abstract] [Full Text] [Related]
5. Drug evaluation: MGCD-0103, a histone deacetylase inhibitor for the treatment of cancer.
Kell J
Curr Opin Investig Drugs; 2007 Jun; 8(6):485-92. PubMed ID: 17621879
[TBL] [Abstract][Full Text] [Related]
6. Edotecarin: a novel topoisomerase I inhibitor.
Saif MW; Diasio RB
Clin Colorectal Cancer; 2005 May; 5(1):27-36. PubMed ID: 15929804
[TBL] [Abstract][Full Text] [Related]
7. Antitumor efficacy of edotecarin as a single agent and in combination with chemotherapy agents in a xenograft model.
Ciomei M; Croci V; Ciavolella A; Ballinari D; Pesenti E
Clin Cancer Res; 2006 May; 12(9):2856-61. PubMed ID: 16675581
[TBL] [Abstract][Full Text] [Related]
8. [NB 506].
Lansiaux A; Bailly C
Bull Cancer; 1999 Mar; 86(3):255-8. PubMed ID: 10210758
[No Abstract] [Full Text] [Related]
9. Becatecarin (Helsinn Healthcare).
Rewcastle GW
IDrugs; 2005 Oct; 8(10):838-47. PubMed ID: 16254805
[TBL] [Abstract][Full Text] [Related]
10. BNP-7787 (BioNumerik/Baxter Oncology/Grelan).
Reilly RT
IDrugs; 2004 Jan; 7(1):64-9. PubMed ID: 14730469
[TBL] [Abstract][Full Text] [Related]
11. SNS-595, a naphthyridine cell cycle inhibitor and stimulator of apoptosis for the treatment of cancers.
Mills DA; Fekrazad HM; Verschraegen CF
Curr Opin Investig Drugs; 2008 Jun; 9(6):647-57. PubMed ID: 18516764
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, biological evaluation, and molecular modeling studies of rebeccamycin analogues modified in the carbohydrate moiety.
Animati F; Berettoni M; Bigioni M; Binaschi M; Felicetti P; Gontrani L; Incani O; Madami A; Monteagudo E; Olivieri L; Resta S; Rossi C; Cipollone A
ChemMedChem; 2008 Feb; 3(2):266-79. PubMed ID: 18157856
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological activities of topoisomerase I inhibitors, 6-arylmethylamino analogues of edotecarin.
Sunami S; Nishimura T; Nishimura I; Ito S; Arakawa H; Ohkubo M
J Med Chem; 2009 May; 52(10):3225-37. PubMed ID: 19397324
[TBL] [Abstract][Full Text] [Related]
14. Possible role of edotecarin, a novel topoisomerase I inhibitor, in therapy-related myelodysplastic syndrome.
Carvajal RD; Ilson DH; Noy A
Leuk Lymphoma; 2007 Jan; 48(1):192-4. PubMed ID: 17325867
[No Abstract] [Full Text] [Related]
15. SCIO-469 Scios Inc.
Nikas SN; Drosos AA
Curr Opin Investig Drugs; 2004 Nov; 5(11):1205-12. PubMed ID: 15573872
[TBL] [Abstract][Full Text] [Related]
16. Indolocarbazole glycosides in inactive conformations.
Facompré M; Carrasco C; Vezin H; Chisholm JD; Yoburn JC; Van Vranken DL; Bailly C
Chembiochem; 2003 May; 4(5):386-95. PubMed ID: 12740810
[TBL] [Abstract][Full Text] [Related]
17. PTK/ZK (Novartis).
Drevs J
IDrugs; 2003 Aug; 6(8):787-94. PubMed ID: 12917775
[TBL] [Abstract][Full Text] [Related]
18. Technology evaluation: PK1, Pfizer/Cancer Research UK.
Bilim V
Curr Opin Mol Ther; 2003 Jun; 5(3):326-30. PubMed ID: 12870445
[TBL] [Abstract][Full Text] [Related]
19. ISIS-3521. Isis Pharmaceuticals.
Li K; Zhang J
Curr Opin Investig Drugs; 2001 Oct; 2(10):1454-61. PubMed ID: 11890365
[TBL] [Abstract][Full Text] [Related]
20. BMS-275291. Bristol-Myers Squibb.
Poulaki V
Curr Opin Investig Drugs; 2002 Mar; 3(3):500-4. PubMed ID: 12054103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
